## James C Sacco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4396197/publications.pdf

Version: 2024-02-01

		1040056	1058476	
15	205	9	14	
papers	citations	h-index	g-index	
15	15	15	221	
15	15	15	321	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Cytochrome b5 and NADH cytochrome b5 reductase: genotype–phenotype correlations for hydroxylamine reduction. Pharmacogenetics and Genomics, 2010, 20, 26-37.	1.5	34
2	SULFONATION OF ENVIRONMENTAL CHEMICALS AND THEIR METABOLITES IN THE POLAR BEAR (Ursus) Tj ETQq	0	Overlock 10
3	Effects of food natural products on the biotransformation of PCBs. Environmental Toxicology and Pharmacology, 2008, 25, 211-217.	4.0	22
4	Glucuronidation of Polychlorinated Biphenylols and UDP-Glucuronic Acid Concentrations in Channel Catfish Liver and Intestine. Drug Metabolism and Disposition, 2008, 36, 623-630.	3.3	22
5	Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity. Pharmacogenetics and Genomics, 2012, 22, 733-740.	1.5	20
6	Polymorphisms in the carcinogen detoxification genes CYB5A and CYB5R3 and breast cancer risk in African American women. Cancer Causes and Control, 2014, 25, 1513-1521.	1.8	14
7	Polymorphisms in the canine monoamine oxidase a (MAOA) gene: identification and variation among five broad dog breed groups. Canine Genetics and Epidemiology, 2017, 4, 1.	2.8	11
8	Glucuronidation in the polar bear (Ursus maritimus). Marine Environmental Research, 2004, 58, 475-479.	2.5	10
9	Individual Variability in the Detoxification of Carcinogenic Arylhydroxylamines in Human Breast. Toxicological Sciences, 2011, 121, 245-256.	3.1	10
10	Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprimâ€sulfamethoxazole prophylaxis. British Journal of Clinical Pharmacology, 2011, 71, 566-574.	2.4	8
11	Dapsoneâ€Associated Methemoglobinemia in a Patient With Slow <i>NAT2 </i> *5B Haplotype and Impaired Cytochrome <i>b</i> 5 Reductase Activity. Journal of Clinical Pharmacology, 2012, 52, 272-278.	2.0	8
12	Genetic and environmental risk for lymphoma in boxer dogs. Journal of Veterinary Internal Medicine, 2020, 34, 2068-2077.	1.6	8
13	Combined ascorbate and glutathione deficiency leads to decreased cytochrome b 5 expression and impaired reduction of sulfamethoxazole hydroxylamine. Archives of Toxicology, 2010, 84, 597-607.	4.2	7
14	Single nucleotide polymorphisms and microsatellites in the canine glutathione S-transferase pi 1 (GSTP1) gene promoter. Canine Genetics and Epidemiology, 2017, 4, 9.	2.8	2
15	Genotypeâ€phenotype correlations for polymorphisms in cytochrome b5 and NADH cytochrome b5 reductase and hepatic sulfamethoxazole hydroxylamine reduction. FASEB Journal, 2008, 22, 919.2.	0.5	0